Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biovet JSCLTS:0III Debt-to-Equity is 0.28 as of Dec. 2016, which is 43% below its 10-year median of 0.49. The stock has 1 warning sign investors should review.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Biovet JSC's Debt-to-Equity or its related term are showing as below:
LTS:0III'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28 Med: 0.49 Max: 0.86
Current: 0.28
During the past 8 years, the highest Debt-to-Equity Ratio of Biovet JSC was 0.86. The lowest was 0.28. And the median was 0.49.
LTS:0III's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28
vs LTS:0III: 0.28
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Biovet JSC Debt-to-Equity Related Terms
Biovet JSC Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Biovet JSC's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0III vs ADMP, AGRX, BUDZ: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Biovet JSC's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biovet JSC (LTS:0III) has a Debt-to-Equity of 0.28 as of Dec. 2016. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biovet JSC and its competitors. This is 43% below median its historical median of 0.49. Over the past decade, Biovet JSC's Debt-to-Equity has ranged from 0.28 to 0.86.
Is Biovet JSC's Debt-to-Equity too high?
Biovet JSC's current Debt-to-Equity of 0.28 is 43% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.86. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Biovet JSC's value of 0.28 is 0% at this industry median.
How does Biovet JSC's Debt-to-Equity compare to ADMP and AGRX?
Biovet JSC's Debt-to-Equity of 0.28 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.28. Biovet JSC's value of 0.28 is 0% at this benchmark. Historically, Biovet JSC's own Debt-to-Equity has ranged from 0.28 to 0.86 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.28, Biovet JSC has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biovet JSC's current Debt-to-Equity of 0.28 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biovet JSC and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current Debt-to-Equity is 0.28, which is 43% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current Debt-to-Equity of 0.28. The current Debt-to-Equity is 0.28, which is 43% below median its 10-year median of 0.49 and 0% at the Drug Manufacturers industry median of 0.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current Debt-to-Equity is 0.28 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 
